

VistaPharm – Recall of sucralfate oral suspension

- On September 22, 2023, <u>VistaPharm announced</u> a consumer-level recall of one lot of <u>sucralfate</u> <u>oral suspension</u> 1 gram/10 mL due to *Bacillus cereus* contamination in the product.
 - Other sucralfate products that are not being recalled are available for patients to use.
- The recalled lots were distributed nationwide.

Product Description	NDC#	Lot # (Expiration Date)
Sucralfate oral suspension 1 gram/10 mL in 16 oz (414 mL)	66689-305-16	810300 (10/31/2023)

- Sucralfate oral suspension is indicated in the short-term (up to 8 weeks) treatment of active duodenal ulcer.
- In the population most at risk, the immunocompromised population, there is a reasonable probability that microbial contamination of the oral suspension can result in disseminated, life threatening infections such as endocarditis and necrotizing soft tissue infections.
- To date, VistaPharm has not received any reports of adverse events related to this recall.
- Anyone with an existing inventory of the recalled product should stop use, distribution and quarantine the product immediately.
- For any questions regarding this recall, contact Inmar (contractor for VistaPharm) by phone at **1**-**800-967-5952** or by email at <u>rxrecalls@Inmar.com</u>.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews[®] is published by the Optum Rx Clinical Services Department.